A Randomized Double Blind Phase 1a Clinical Trial of THR-18, a PAI-1 Derived peptide, in Normal Volunteers

Trial Profile

A Randomized Double Blind Phase 1a Clinical Trial of THR-18, a PAI-1 Derived peptide, in Normal Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2012

At a glance

  • Drugs THR 18 (Primary)
  • Indications Myocardial infarction; Stroke; Thrombosis
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Feb 2012 Results published in the World Wide Web [online].
    • 07 Sep 2010 Results published in a media release.
    • 01 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top